LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Home・Список акций・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Закрыт

СекторЗдравоохранение

1.41 -2.08

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

1.41

Макс.

1.51

Ключевые показатели
By Trading Economics
Доход	9.5M -41M
Рентабельность продаж	272,450
Сотрудники	226
EBITDA	19M -38M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+532.41% upside

Рыночная статистика
By TradingEconomics
Рыночная капитализация	64M 326M
Предыдущая цена открытия	3.49
Предыдущая цена закрытия	1.41

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

1.18 / 1.69 Поддержка и Сопротивление

Allogene Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

9 дек. 2025 г., 22:13 UTC

Отчет

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9 дек. 2025 г., 21:40 UTC

Отчет

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9 дек. 2025 г., 18:51 UTC

Приобретения, слияния, поглощения

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9 дек. 2025 г., 16:57 UTC

Главные движущие силы рынка

Clear Secure Rises on Medicare Identity Verification Contract

9 дек. 2025 г., 23:46 UTC

Обсуждения рынка

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9 дек. 2025 г., 23:46 UTC

Приобретения, слияния, поглощения

Legend Holdings Stake in Lenovo Now at 32.34%

9 дек. 2025 г., 23:45 UTC

Приобретения, слияния, поглощения

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9 дек. 2025 г., 23:44 UTC

Приобретения, слияния, поглощения

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9 дек. 2025 г., 23:43 UTC

Приобретения, слияния, поглощения

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9 дек. 2025 г., 23:43 UTC

Приобретения, слияния, поглощения

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9 дек. 2025 г., 23:35 UTC

Обсуждения рынка

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9 дек. 2025 г., 22:42 UTC

Отчет

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9 дек. 2025 г., 21:50 UTC

Обсуждения рынка

Tech, Media & Telecom Roundup: Market Talk

9 дек. 2025 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

9 дек. 2025 г., 21:48 UTC

Обсуждения рынка

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9 дек. 2025 г., 21:36 UTC

Отчет

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9 дек. 2025 г., 21:36 UTC

Отчет

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9 дек. 2025 г., 21:36 UTC

Отчет

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9 дек. 2025 г., 21:36 UTC

Отчет

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9 дек. 2025 г., 21:36 UTC

Отчет

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9 дек. 2025 г., 20:28 UTC

Обсуждения рынка

Oil Futures Decline for Second Straight Session -- Market Talk

9 дек. 2025 г., 20:27 UTC

Приобретения, слияния, поглощения

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9 дек. 2025 г., 20:27 UTC

Приобретения, слияния, поглощения

Teck Reports Voting Results From Special Meeting of Hldrs

9 дек. 2025 г., 20:26 UTC

Обсуждения рынка

Приобретения, слияния, поглощения

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9 дек. 2025 г., 20:21 UTC

Обсуждения рынка

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9 дек. 2025 г., 19:52 UTC

Отчет

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9 дек. 2025 г., 19:17 UTC

Отчет

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9 дек. 2025 г., 17:20 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

9 дек. 2025 г., 17:15 UTC

Обсуждения рынка

Global Commodities Roundup: Market Talk

9 дек. 2025 г., 17:11 UTC

Отчет

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Сравнение c конкурентами

Изменение цены

Allogene Therapeutics Inc Прогноз

Целевая цена

By TipRanks

532.41% рост

Прогноз на 12 месяцев

Средняя 9.17 USD 532.41%

Максимум 14 USD

Минимум 7 USD

Основано на мнении 8 аналитиков Wall Street, спрогнозировавших целевые цены для Allogene Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

8 ratings

Покупка

Удержание

Продажа

Основано на мнении 8 аналитиков, присваивавших рейтинги акциям Allogene Therapeutics Inc – Данные за последние 3 месяца.

Техническая оценка

By Trading Central

1.18 / 1.69Поддержка и Сопротивление

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.